Live feed06:45:00·16dPRReleasevia QuantisnowACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthByQuantisnow·Wall Street's wire, on your screen.LLY· Eli Lilly and CompanyHealth Care
